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Tiotropium; more knowledge leads to more questions
This issue of the International Journal of COPD has 3 original research papers that 
study the effects of tiotropium. These papers are very different, addressing the effect 
of tiotropium on the small airways (Incorvaia et al 2008), the beneﬁ  t of additional 
tiotropium treatment during a pulmonary rehabilitation programme (Kesten et al 2008), 
and the effect of tiotropium when prescribed to patients already taking theophylline 
(Kawayama et al 2008). Each paper offers new information about the effects of tiotro-
pium, but also leads us towards further questions that need answering.
Incorvaia and colleagues (2007) had previously shown that tiotropium has greater 
effects than oxitropium on FEF25-75, a measurement of small airway function. In 
the current issue, this observation is further extended as treatment with tiotropium 
for 3 months was found to improve FEF25-75 in patients with frequent exacerbations 
(2 exacerbations per year) (Incorvaia et al 2008). Interestingly, FEF25-75 before 
treatment with tiotropium was signiﬁ  cantly lower in patients with frequent exacerba-
tions compared to those with 2 exacerbations per year. This suggests that frequent 
exacerbations are associated with small airway dysfunction that can be improved by 
tiotropium. The limitations of the study are a small sample size, and the statistics 
used only evaluated changes within a group, not between frequent and infrequent 
exacerbators.
There is other data recently published that also shows the beneﬁ  t of tiotropium 
on small airway function (Borrill et al 2008). The physiological beneﬁ  ts of improved 
small airway function include improved lung mechanics by reducing hyperinﬂ  ation, 
thus reducing symptoms (Matlais et al 2005). Less clear is the question of whether 
improved small airway function can actually reduce exacerbation rates. Tiotropium is 
known to reduce exacerbation rates (Brusasco et al 2003), but this effect does not seem 
to be mediated by a change in the proﬁ  le of inﬂ  ammatory cells in the airways (Powrie 
et al 2007). So how does tiotropium reduce exacerbations? Mucus hypersecretion is 
known to be a risk factor for exacerbations (Seemungal et al 1998; Foreman at al 2007), 
and perhaps tiotropium by its anticholinergic action alters alters mucus production or 
mucus clearance by improving small airway function. These are important questions 
that need answering.
Casaburi and colleagues (2005) had previously shown that tiotropium in com-
bination with pulmonary rehabilitation improved pulmonary function and exercise 
endurance compared to rehabilitation alone. A subgroup analysis is presented in this 
issue focusing on the group of patients who also completed a self reported exercise 
participation questionnaire (Kesten et al 2008). There were signiﬁ  cant increases in 
activity duration in the tiotropium but not the placebo group, although between group 
differences were not signiﬁ  cant. This was a subset analysis that was not statistically 
powered, and so must be considered as exploratory data. The well validated measure-
ments of health status and breathlessness (St Georges Respiratory Questionnaire and 
Dyspnoea Index, respectively) did show a beneﬁ  t for tiotropium over placebo. Overall, 
the extra beneﬁ  ts of tiotropium therapy during a pulmonary rehabilitation programme 
are clear. This leads us to the question of optimising medical therapy during rehabilita-
tion to achieve maximum beneﬁ  ts. “Combination therapy” in COPD is often thought 
of as involving drug treatments. However, a good combination therapy also appears 
to be tiotropium plus rehabilitation.International Journal of COPD 2008:3(1)  ii
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Kawayama and colleagues (2008) studied the effect of 
add on therapy with tiotropium in patients already taking 
theophylline. Meta-analysis show that theophylline has 
beneﬁ  cial therapeutic effects in COPD (Molﬁ  no and Zhang 
2006). Consequently, theophylline is widely prescribed 
in Japan, so adding tiotropium to theophylline is common 
practice. There were improvements in lung function and 
symptoms with tiotropium, but the study suffers from not 
having a tiotropium alone (without theophylline) treatment 
arm. Cazzola and Gabriella Matera (2007) showed that add-
ing theophylline to tiotropium plus formoterol had no effect, 
although in a different study there was some beneﬁ  t when 
theophylline was added to salmeterol (Zuwallack et al 2001). 
The merits of theophylline combination therapy with long 
acting bronchodilators remains unclear, and perhaps the best 
prospect for combination therapy involving theophylline is 
with corticosteroids, as theophylline may enhance cortico-
steroid effects (Cosio et al 2004).
The future of COPD therapy for patients with more severe 
disease appears to be combination therapy approaches. The 
most promising combinations that include tiotropium appear 
to be “triple therapy” with a long-acting beta agonist and 
inhaled corticosteroid, which improves pulmonary function 
and symptoms more than the individual components (Aaron 
et al 2007; Cazzola et al 2007; Singh et al 2008). The long 
term beneﬁ  ts of such a “triple therapy” approach needs to be 
evaluated in properly powered studies of exacerbation rates. 
Maybe we should consider “quadruple therapy”, if we add 
in pulmonary rehabilitation.
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